Latest developments in COVID-19 research
As COVID-19 continues to evolve, researchers are still on the lookout for new ways to protect against the virus. Drug Target Review brings you some of the most recent pre-clinical developments.
List view / Grid view
As COVID-19 continues to evolve, researchers are still on the lookout for new ways to protect against the virus. Drug Target Review brings you some of the most recent pre-clinical developments.
Drug Target Review’s Ria Kakkad recently spoke with Dr Jane Osbourn about her experience as a woman in STEM.
Researchers find monoclonal antibodies provided nearly complete protection against EBV infection and lymphoma when tested in mice.
The study highlights that a monoclonal antibody that targets heroin is effective in blocking the psychoactive and lethal effects of drug abuse in mice.
A recently discovered SARS-CoV-2 virus in a Russian bat is likely to be capable of infecting humans and resistant to current vaccines.
Antibody therapy has been a critical part of the COVID-19 research campaign to treat severe cases. Unfortunately, despite many promising candidates, scientists have yet to find one that passes clinical trials. This article by Drug Target Review’s Ria Kakkad highlights some of the most recent developments in the search for COVID-19…
While the introduction of novel immunotherapies to combat and treat cancer has advanced patient care greatly, ever more effective solutions continue to be required. Here, Dr Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology at Janssen Europe, Middle East & Africa (EMEA), explores how T-cell redirecting bispecific antibodies (TRBAs)…
In this exclusive Q&A, Dr Veysel Kayser, Associate Professor at the University of Sydney, Australia, outlines why monoclonal antibodies (mAbs) are such an important tool to combat cancer. He also relates his recent research, as well as the latest trends in the industry.
In this ebook are articles on why monoclonal antibodies represent a high level of promise in the fight against cancer and how T-cell redirecting bispecific antibodies could work as a new immunotherapeutic strategy against haematological conditions.
The monoclonal antibody 19A11 binds E-cadherin, a protein that helps cells stick together, especially in epithelial layers that line the skin, the gut and other organs.
The scientists found that the neutralising monoclonal antibody protected against SARS-CoV-2 infections in animal experiments.
Listen to this podcast to discover why mAbs are key in the fight against SARS-CoV-2 and how the pandemic has shaped their development pipeline.
In this article, Dr Shishir Chundawat and Aron Gyorgypal from Rutgers University, US, explain how they developed a new process analytical technology (PAT) system for the automated monitoring of antibody N-glycosylation.
Sino Biological, Inc. has just launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-CoV-2 virus, which quickly raised concerns around the world due to the high number of mutations it carries, particularly the 30-plus mutations on the Spike protein.
In this ebook, find an article on 3D tissue cultures from biopsy samples to evaluate the preservation of tissue-typical protein expressions as well as a piece on a new process analytical technology (PAT) system to assess N-glycosylation during upstream cell culture bioprocessing.